A site where you can find recommended contractors for non-clinical testing｜effical " list of animal models " icv-STZ

icv-STZ

This article introduces the "icv-STZ" model, which is a pathological model of Alzheimer's disease (neuroinflammation). We have investigated and compiled information on its characteristics, research subjects, and main products.

icv-STZ

Evaluation of the pharmacological efficacy of candidate drugs in early-stage sporadic Alzheimer's diseaseThis is a model used for Alzheimer's disease. Sporadic Alzheimer's disease accounts for the majority of Alzheimer's disease cases, but it is believed to be caused mainly by aging and environmental factors, without clear genetic mutations.

The icv-STZ model, characterized by its similarity to sporadic Alzheimer's disease,Evaluation of drugs targeting neurological disorders, gliosis, brain inflammation, neuronal and synaptic loss, and mild cognitive impairmentis said to be suitable for performing.

The main subjects of research utilization

Diseases for research	How to use a disease model
Sporadic Alzheimer's disease	Pharmacological efficacy of a novel compound for early to moderate sporadic Alzheimer's disease independent of genetic mutations
Mild cognitive impairment and dementia	Screening of novel drug candidates for spatial memory and learning impairments, and elucidation of the mechanisms for cognitive function improvement.
Cerebral insulin resistance	Elucidation of the pathogenic mechanisms of impaired brain-specific insulin signaling

This model is primarily used for evaluating the efficacy of new compounds for sporadic Alzheimer's disease and dementia, and for analyzing the mechanisms of the disease.

How to use	Details
Pharmacological action Cognitive function and memory disorder evaluation	Spatial memory and working memory assessment using the Y-maze test and Morris water maze test Evaluation of long-term memory and learning ability using the passive avoidance test and novel object recognition test
Histopathological analysis of brain tissue	Evaluation of astrocyte activation by GFAP immunostaining Evaluation of microglial activation and neuroinflammation progression by Iba1 immunostaining Evaluation of neuronal loss in the hippocampus and other areas using NeuN and Nissl staining

icv-STZ Review

Effects of streptozotocin (STZ) administration on behavior and energy metabolism

Sporadic Alzheimer's disease is associated with impaired brain energy metabolism and insulin receptor signaling, which contribute to the onset of dementia. This study evaluates the effects on behavior and energy metabolism after administering streptozotocin (STZ), which impairs insulin receptor function, into the brain ventricles of rats.

As a result, icv-STZ-treated rats showed significantly impaired performance in the holeboard test and the passive avoidance test,Long-term and progressive learning and memory impairment, persistent energy deficiencyshows. From studies like this, this animal modelUseful in the study of sporadic Alzheimer's diseaseIt is concluded that

Reference: National Library of Medicine
https://pubmed.ncbi.nlm.nih.gov/9829797/

icv-STZ Main Products

Here, we introduce two products from the top 10 Google search results for "icv-STZ product," which had product pages confirmed, presented in order of search ranking (searched on June 4, 2026).

ICV-STZ model (ICV-STZ-induced Alzheimer's disease model)

Disease model that induces brain inflammation, synaptic loss, and mild cognitive impairment in a short period by administering STZ into the brain ventricles. It exhibits a pathology similar to sporadic Alzheimer's disease, which differs from familial forms, and is used for evaluating the efficacy of novel drug candidates targeting brain inflammation and neurodegeneration.

Manufacturer/Distributor	Analysis items	Primary Endpoint
SMC Laboratories, Inc.	Weight change, memory impairment assessment, hippocampal histopathological analysis	Improvement of memory and cognitive function, suppression of astrogliosis and microglial activation (neuroinflammation) in the hippocampus

Reference: SMC Laboratories, Inc.
https://www.smccro-lab.com/jp/modellineup/icv-stz-model/

Streptozotocin (STZ)-Induced Rodent Alzheimer's Disease Model

This is an animal model used for evaluating Alzheimer's disease, which is provided for preclinical studies. Intracerebral administration of STZ inhibits insulin signaling in the brain, thereby reproducing cognitive decline and cholinergic neuron dysfunction.

Manufacturer/Distributor	Analysis items	Primary Endpoint
Creative Biolabs	Behavioral assessment tests, biochemical analysis of blood and brain tissue	Improvement of cognitive and memory functions, suppression of neuroinflammation, and normalization of neurotransmitter dynamics

Reference: Creative Biolabs
https://www.creative-biolabs.com/drug-discovery/therapeutics/streptozotocin-alzheimers-disease-modeling-pharmacodynamic-service.htm

Summary

The icv-STZ model is a pathological model that reproduces cognitive impairment and neuroinflammation in sporadic Alzheimer's disease by inducing insulin resistance through the administration of STZ to the brain, and is widely used in the development of new drugs.In non-clinical studies, the selection of reliable models is important.This article introduces a list of disease models used in non-clinical studies, which you can use as a reference.

List of pathological models used in non-clinical studies

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us